Drug Trial Radar · NCT03898856
Yield of Diagnostic Tests and Effects of Crofelemer for Chronic Idiopathic Diarrhea In Non-HIV Patients
Last checked: Nov 19, 2026Latest source record: Feb 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
93
Actual
Start
Apr 1, 2019
Primary completion
Jan 30, 2025
Study completion Jan 30, 2025
Sponsor
- Lead sponsor
- The University of Texas Health Science Center, HoustonAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Napo Pharmaceuticals, Inc.
- First posted
- Apr 2, 2019
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the effectiveness of the drug Crofelemer in the treatment of non-HIV patients with chronic idiopathic diarrhea; to determine the prevalence of identifiable causes of chronic diarrhea in a non-HIV patients; to assess the diagnostic yield, in terms of identification of treatable etiologies, of commercially available diagnostic evaluations in adult, non-HIV patients with chronic idiopathic diarrhea, that is, evaluate which tests, among the standard diagnostic tests commonly conducted as part of the evaluation of chronic idiopathic diarrhea, are most likely to identify a treatable cause of the diarrhea; and to analyze the relationship between chronic idiopathic diarrhea and health-related quality of life and assess the impact of crofelemer treatment on health-related quality of life.
Conditions
- Chronic Diarrhea of Unknown Origin
Interventions
CrofelemerDrug
125 mg tablets taken by mouth twice daily for 28 days
Diagnostic tests for cause of chronic diarrheaDiagnostic test
Diagnostic tests include: Esophagogastroduodenoscopy, Colonoscopy, biopsies of the upper gastrointestinal tract (duodenum) and lower gastrointestinal tract (colon), genetic testing for Congenital sucrase-isomaltase deficiency (CSID),Prometheus IBcause Chronic Diarrhea panel, Thyroid Panel, Stool osmolality, Stool Ova and Parasites, Stool Culture, Stool Qualitative Stool Fat, Stool Reducing Substances, Laxative Screening, Lactulose Hydrogen Breath Test, Gastrin Level, Calcitonin Level, Vasoactive Intestinal Polypeptide(VIP) level.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With a 50 Percent Decrease in Mean Stool CountTime frame: Week 1
- Number of Participants With a 50 Percent Decrease in Mean Stool CountTime frame: Week 2
- Number of Participants With a 50 Percent Decrease in Mean Stool CountTime frame: Week 3
- Number of Participants With a 50 Percent Decrease in Mean Stool CountTime frame: Week 4
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The University of Texas Health Science Center at Houston
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.